United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - leflunomide (unii: g162gk9u4w) (leflunomide - unii:g162gk9u4w) - leflunomide 99 g in 100 g

Canada - English - Health Canada

sanis health inc - leflunomide - tablet - 10mg - leflunomide 10mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

sanis health inc - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents

United States - English - NLM (National Library of Medicine)

v2 pharma, llc - leflunomide (unii: g162gk9u4w) (leflunomide - unii:g162gk9u4w) - leflunomide tablets usp are indicated for the treatment of adults with active rheumatoid arthritis (ra). the recommended dosage of leflunomide tablets usp is 20 mg once daily. treatment may be initiated with or without a loading dose, depending upon the patient's risk of leflunomide tablets usp -associated hepatotoxicity and leflunomide tablets -associated myelosuppression. the loading dosage provides steady-state concentrations more rapidly. for patients who are at low risk for leflunomide tablets -associated hepatotoxicity and leflunomide tablets usp - associated myelosuppression the recommended leflunomide tablets usp loading dosage is 100 mg once daily for 3 days. subsequently administer 20 mg once daily. for patients at high risk for leflunomide tablets usp -associated hepatotoxicity (e.g., those taking concomitant methotrexate) or leflunomide tablets -associated myelosuppression (e.g., patients taking concomitant immunosuppressants), the recommended leflunomide tablets usp dosage is 20 mg once daily w

Israel - English - Ministry of Health

sanofi israel ltd - leflunomide - film coated tablets - leflunomide 10 mg - leflunomide - leflunomide - arava is indicated in adults for the treatment of active rheumatoid arthritis (ra) : 1. to reduce signs and symptoms 2. to inhibit structural damage as evidenced by x-ray erosions and joint space narrowing 3. to imptove physical function. arava is indicated for the treatment of adult patients with active psoriatic arthritis.

Israel - English - Ministry of Health

sanofi israel ltd - leflunomide - film coated tablets - leflunomide 20 mg - leflunomide - leflunomide - arava is indicated in adults for the treatment of active rheumatoid arthritis (ra) : 1. to reduce signs and symptoms 2. to inhibit structural damage as evidenced by x-ray erosions and joint space narrowing 3. to imptove physical function. arava is indicated for the treatment of adult patients with active psoriatic arthritis.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - leflunomide, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; maize starch; magnesium stearate; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions). lunava is not indicated for the treatment of psoriatic arthritis or psoriasis (whether or not associated with manifestations of psoriatic arthritis).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - leflunomide, quantity: 20 mg - tablet, film coated - excipient ingredients: povidone; colloidal anhydrous silica; maize starch; microcrystalline cellulose; magnesium stearate; crospovidone; lactose monohydrate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - treatment of active rheumatoid arthritis. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions). lunava is not indicated for the treatment of psoriatic arthritis or psoriasis (whether or not associated with manifestations of psoriatic arthritis).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - leflunomide, quantity: 10 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; povidone; magnesium stearate; crospovidone; lactose monohydrate; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions). lunava is not indicated for the treatment of psoriatic arthritis or psoriasis (whether or not associated with manifestations of psoriatic arthritis).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 20 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; maize starch; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).